Navigation Links
Monoclonal antibodies show promise in treatment of blood cancer

Immunologists at Duke University Medical Center have found that a new monoclonal antibody that targets immune system B cells could be a pioneering treatment for leukemias, autoimmune diseases and transplant rejection//.

B cells are the main producers of antibodies, the body's defense mechanism against invading antigens. But the uncontrolled production of these B cells is responsible for leukemias such as multiple myeloma and acute lymphoblastic leukemia and autoimmune diseases like rheumatoid arthritis and lupus. The findings of the study have been published in the online Early Edition of the Proceedings of the National Academy of Sciences for the week October 10, 2005.

Professor and Chair of Immunology Thomas Tedder, Ph.D., Norhito Yazawa, Yasuhito Hamaguchi and Jonathan Poe in Tedder's laboratory are the co-authors of this report. Basically, monoclonal antibodies are directed against specific proteins. In this study, the Duke researchers targeted a surface protein called CD19, which is found on the B cells. When this was administered to laboratory mice, the researchers found that this reduced the number of B cells greatly. Significantly they also found that this monoclonal antibody behaved aggressively against B cell tumors. In 10 mice with malignant B cell lymphomas, the monoclonal antibody prevented the appearance of tissue tumor circulating cells for seven weeks. In contrast untreated mice died in three weeks. "We were actually quite shocked at how effectively CD19 mAb-treatments prevented malignant B cell expansion," said Tedder. "Treatment of such tumors in mouse models is extraordinarily difficult." Based on their findings, the researchers conclude, "In addition, this treatment could greatly aid transplant patients who require multiple organ transplants because they develop a humoral antibody response to their transplanted organs, or they already have preformed antibodies that prevent them from accepting some donor grafts."
'"/>




Page: 1

Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
3. Monoclonal Antibody based system for Anthrax detection
4. Monoclonal Antibody Reduces Exacerbations in Asthmatics
5. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
6. Mutating viruses helps produce antibodies
7. Hybrid antibodies to protect from small pox infection
8. Gene Therapy shows promise in treating Hemophilia
9. Leukemia pill shows promise against stomach cancer
10. Stent shows promise in keeping arteries open
11. Drug to treat lung cancer shows promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/28/2017)... ... July 28, 2017 , ... Shamanic Teacher Anahata Ananda of ... is proud to announce the return of her increasingly popular “Shamanic Wisdom ... more about the mystical world of shamanism, nature wisdom, the medicine wheel, energy ...
(Date:7/27/2017)... ... July 27, 2017 , ... Dr. ... Board of Oral Implantology/Implant Dentistry (ABOI/ID). After successfully completing an extensive two-day examination ... of dental implants . Dr. Kimowitz and his partner Dr. Hal Kimowitz, ...
(Date:7/27/2017)... Longview, TX (PRWEB) , ... July 27, 2017 ... ... to receive a new set of teeth in a single office visit from ... convenient and comfortable treatment solutions to his East Texas patients, including Teeth-in-a-Day® ...
(Date:7/27/2017)... ... July 28, 2017 , ... DMG Productions is pleased to ... television series, American Famer, scheduled to broadcast fourth quarter 2017. American Farmer airs ... helping humanity face its toughest challenge: how to feed a rising population in ...
(Date:7/27/2017)... ... 27, 2017 , ... SSCI, a division of Albany Molecular ... worldwide, representing a milestone achievement. , As an industry-leading provider of ... have served as expert and fact witnesses to assist our clients to perform ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... It should come as no surprise to anyone ... the midst of a crippling opioid epidemic. According to the ... of overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... dead from 2001 to 2015". During this time, the prescription ... quadrupled, drawing a compelling link between prescription and eventual addiction. ...
(Date:7/12/2017)... July 12, 2017  Eli Lilly and Company (NYSE: ... generic companies to resolve pending patent litigation in the U.S. ... regarding the Cialis ® (tadalafil) unit dose ... 26, 2020. As part of the agreement, Cialis exclusivity is ... 2018. "The unit dose patent for Cialis is ...
Breaking Medicine Technology: